Qinghong Meng

Oct 26, 2024 | journalofinfection.com | Wei Shi |Xinyu Wang |Kaihu Yao |Qinghong Meng |Yahong Hu |Guoshuang Feng

Dear Editor,The resurgence of pertussis in China was recently reported in this Journal.1 Actually, several countries has witnessed a significant resurgence of pertussis since 2023,2,3 with some experiencing multiple fatalities in a short period.4,5 In the first eight months of 2024 alone, China reported 452,396 cases of pertussis, including 24 deaths (https://www.ndcpa.gov.cn/jbkzzx/c100016/second/list.html).

Jul 2, 2024 | journalofinfection.com | Qinghong Meng |Wei Shi |Yahong Hu |Kaihu Yao

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

May 6, 2024 | journalofinfection.com | Wei Shi |Qinghong Meng

Highlights•Macrolides should NOT continue to be the first choice for the empirical treatment of pertussis in China. •Trimethoprim-sulfamethoxazole is recommended for current pertussis treatment in China. •Beta-lactam drugs are effective for most ERBP infections and can be used as an alternative therapy. •Research on other pertussis treatments should be promoted immediately in China.